Short Interest in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Decreases By 77.1%

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 1,900 shares, a decline of 77.1% from the May 15th total of 8,300 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 43,400 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Wall Street Zen started coverage on Titan Pharmaceuticals in a research note on Tuesday, May 20th. They set a “sell” rating on the stock.

Titan Pharmaceuticals Stock Performance

Shares of TTNP stock opened at $4.40 on Friday. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80. The firm has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.96 and a beta of 1.30. The stock’s 50-day simple moving average is $4.23 and its 200-day simple moving average is $3.82.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.